Germline Mutations in CIDEB and Protection against Liver Disease.

Area of Science:

• Genetics
• Hepatology
• Biochemistry

Background:

• Exome sequencing in large populations can identify rare genetic variants linked to disease protection.
• Identifying protective variants offers a strategy for discovering novel therapeutic targets for human diseases like liver cirrhosis.

Purpose of the Study:

• To identify genes with rare protein-coding variants associated with liver phenotypes using exome sequencing and genetic association analysis.
• To characterize the functional impact of identified genetic variants through in vitro experiments.

Main Methods:

• Multistage exome sequencing and genetic association analysis in over 500,000 individuals, including patients with liver disease and controls.
• In vitro experiments using human hepatoma cell lines to investigate the role of CIDEB in lipid metabolism.

Main Results:

• Rare coding variants in APOB, ABCB4, SLC30A10, and TM6SF2 were associated with increased liver aminotransferase levels and liver disease risk.
• Rare coding variants in CIDEB demonstrated a protective effect, significantly decreasing alanine aminotransferase levels and reducing the odds of liver disease, including cirrhosis.
• CIDEB variants were also associated with reduced nonalcoholic fatty liver disease activity scores in patients who underwent bariatric surgery.

Conclusions:

• Rare germline mutations in CIDEB provide substantial protection against liver disease.
• CIDEB represents a promising therapeutic target for the prevention and treatment of various liver conditions.